These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 18981772)
1. Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. Greenbaum AH; Wilson LE; Keruly JC; Moore RD; Gebo KA AIDS; 2008 Nov; 22(17):2331-9. PubMed ID: 18981772 [TBL] [Abstract][Full Text] [Related]
2. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Nachega JB; Hislop M; Dowdy DW; Chaisson RE; Regensberg L; Maartens G Ann Intern Med; 2007 Apr; 146(8):564-73. PubMed ID: 17438315 [TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S; PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720 [TBL] [Abstract][Full Text] [Related]
4. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. Mussini C; Manzardo C; Johnson M; Monforte Ad; Uberti-Foppa C; Antinori A; Gill MJ; Sighinolfi L; Borghi V; Lazzarin A; Miró JM; Sabin C; AIDS; 2008 Nov; 22(18):2461-9. PubMed ID: 19005269 [TBL] [Abstract][Full Text] [Related]
5. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. Tuboi SH; Harrison LH; Sprinz E; Albernaz RK; Schechter M J Acquir Immune Defic Syndr; 2005 Nov; 40(3):324-8. PubMed ID: 16249707 [TBL] [Abstract][Full Text] [Related]
6. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235 [TBL] [Abstract][Full Text] [Related]
8. Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). Pulido F; Arribas JR; Miró JM; Costa MA; González J; Rubio R; Peña JM; Torralba M; Lonca M; Lorenzo A; Cepeda C; Vázquez JJ; Gatell JM; J Acquir Immune Defic Syndr; 2004 Apr; 35(4):343-50. PubMed ID: 15097150 [TBL] [Abstract][Full Text] [Related]
9. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777 [TBL] [Abstract][Full Text] [Related]
10. Higher Risks of Virologic Failure and All-Cause Deaths Among Older People Living with HIV in Chongqing, China. Wu G; Zhou C; Zhang X; Zhang W; Lu R; Ouyang L; Xing H; Shao Y; Ruan Y; Qian HZ AIDS Res Hum Retroviruses; 2019; 35(11-12):1095-1102. PubMed ID: 31544479 [TBL] [Abstract][Full Text] [Related]
11. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. Sterling TR; Chaisson RE; Moore RD AIDS; 2001 Nov; 15(17):2251-7. PubMed ID: 11698698 [TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Grabar S; Le Moing V; Goujard C; Leport C; Kazatchkine MD; Costagliola D; Weiss L Ann Intern Med; 2000 Sep; 133(6):401-10. PubMed ID: 10975957 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. Tan R; Westfall AO; Willig JH; Mugavero MJ; Saag MS; Kaslow RA; Kempf MC J Acquir Immune Defic Syndr; 2008 Apr; 47(5):553-8. PubMed ID: 18285713 [TBL] [Abstract][Full Text] [Related]
14. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Moore RD; Keruly JC Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456 [TBL] [Abstract][Full Text] [Related]
15. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. Hung CC; Chen MY; Hsiao CF; Hsieh SM; Sheng WH; Chang SC AIDS; 2003 Dec; 17(18):2615-22. PubMed ID: 14685055 [TBL] [Abstract][Full Text] [Related]
16. Virologic and immunologic response to HAART, by age and regimen class. Althoff KN; Justice AC; Gange SJ; Deeks SG; Saag MS; Silverberg MJ; Gill MJ; Lau B; Napravnik S; Tedaldi E; Klein MB; Gebo KA; AIDS; 2010 Oct; 24(16):2469-79. PubMed ID: 20829678 [TBL] [Abstract][Full Text] [Related]
17. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy. Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267 [TBL] [Abstract][Full Text] [Related]
18. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Jaspan HB; Berrisford AE; Boulle AM Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556 [TBL] [Abstract][Full Text] [Related]
19. Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States. Melekhin VV; Shepherd BE; Jenkins CA; Stinnette SE; Rebeiro PF; Bebawy SS; Rasbach DA; Hulgan T; Sterling TR AIDS Patient Care STDS; 2010 May; 24(5):279-86. PubMed ID: 20438375 [TBL] [Abstract][Full Text] [Related]
20. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]